By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



99 Hayden Avenue
Suite 390
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-357-2333 Fax: 781-357-2399



Company News
Ruthigen And Pulmatrix Enter Into Merger Agreement 3/16/2015 7:00:36 AM
Pulmatrix Presents Preclinical Data On iSPERSE Inhaled Antibiotics At The 2014 Respiratory Drug Delivery Conference 5/5/2014 9:56:32 AM
Pulmatrix's PUR0200 Demonstrated Encouraging Results In Phase 1B Clinical Study In COPD Patients 5/5/2014 9:52:38 AM
Pulmatrix Announces Positive Results From Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients 10/28/2013 10:42:33 AM
Quotient Clinical Announces RapidFACT Collaboration With Pulmatrix to Develop a New Bronchodilator Therapy for COPD 8/13/2013 8:59:43 AM
Pulmatrix Announces Initiation of Phase IB Clinical Study of PUR0200 in COPD 7/22/2013 9:38:35 AM
Cystic Fibrosis Foundation Therapeutics, Inc. and Pulmatrix Initiate Collaboration to Accelerate PUR118 in the Treatment of Cystic Fibrosis 9/14/2012 9:05:27 AM
Quotient and Pulmatrix Announce Completion of Innovative COPD Proof-of-Concept Clinical Program 9/4/2012 12:41:21 PM
Pulmatrix Taps Robert Clarke, Ph.D. CEO, Releases Promising Data on Lung Drug 9/4/2012 7:34:14 AM
Pulmatrix Announces Presentations at European Respiratory Society Annual Congress for Lead Inhaled iCALM Drug Candidate, PUR118 8/27/2012 10:13:24 AM